首页> 美国卫生研究院文献>European Journal of Human Genetics >Current issues in medically assisted reproduction and genetics in Europe: research clinical practice ethics legal issues and policy
【2h】

Current issues in medically assisted reproduction and genetics in Europe: research clinical practice ethics legal issues and policy

机译:欧洲医学辅助生殖和遗传学的当前问题:研究临床实践伦理法律问题和政策

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In March 2005, a group of experts from the European Society of Human Genetics and European Society of Human Reproduction and Embryology met to discuss the interface between genetics and assisted reproductive technology (ART), and published an extended background paper, recommendations and two Editorials. Seven years later, in March 2012, a follow-up interdisciplinary workshop was held, involving representatives of both professional societies, including experts from the European Union Eurogentest2 Coordination Action Project. The main goal of this meeting was to discuss developments at the interface between clinical genetics and ARTs. As more genetic causes of reproductive failure are now recognised and an increasing number of patients undergo testing of their genome before conception, either in regular health care or in the context of direct-to-consumer testing, the need for genetic counselling and preimplantation genetic diagnosis (PGD) may increase. Preimplantation genetic screening (PGS) thus far does not have evidence from randomised clinical trials to substantiate that the technique is both effective and efficient. Whole-genome sequencing may create greater challenges both in the technological and interpretational domains, and requires further reflection about the ethics of genetic testing in ART and PGD/PGS. Diagnostic laboratories should be reporting their results according to internationally accepted accreditation standards (International Standards Organisation – ISO 15189). Further studies are needed in order to address issues related to the impact of ART on epigenetic reprogramming of the early embryo. The legal landscape regarding assisted reproduction is evolving but still remains very heterogeneous and often contradictory. The lack of legal harmonisation and uneven access to infertility treatment and PGD/PGS fosters considerable cross-border reproductive care in Europe and beyond. The aim of this paper is to complement previous publications and provide an update of selected topics that have evolved since 2005.
机译:2005年3月,来自欧洲人类遗传学会和欧洲人类生殖与胚胎学会的专家组举行会议,讨论了遗传学与辅助生殖技术(ART)之间的接口,并发表了扩展的背景文件,建议和两项社论。七年后的2012年3月,举行了后续跨学科讲习班,两个专业协会的代表参加了会议,其中包括欧洲联盟Eurogentest2协调行动项目的专家。这次会议的主要目的是讨论临床遗传学与抗逆转录病毒疗法之间的联系。由于现在已经认识到生殖功能衰竭的更多遗传原因,并且越来越多的患者在受孕之前接受基因组测试,无论是在常规医疗保健中还是在直接面向消费者的测试中,都需要进行遗传咨询和植入前遗传学诊断(PGD)可能会增加。迄今为止,植入前基因筛查(PGS)尚无来自随机临床试验的证据来证实该技术既有效又有效。全基因组测序可能会在技术和解释领域带来更大的挑战,并且需要进一步反思ART和PGD / PGS中的基因检测伦理。诊断实验室应根据国际认可的认证标准(国际标准组织– ISO 15189)报告其结果。为了解决与ART对早期胚胎的表观遗传重编程影响有关的问题,需要进行进一步的研究。关于辅助生殖的法律格局正在不断发展,但仍然非常不同并且经常相互矛盾。缺乏法律上的统一以及不孕治疗和PGD / PGS的获取不均,在欧洲及其他地区促进了相当多的跨境生殖保健。本文的目的是补充以前的出版物,并提供自2005年以来不断发展的精选主题的更新。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号